Ted Monohon
CIK 1606905 · Chief Accounting Officer & VP · last filed 2023-03-06
Ted Monohon is a Chief Accounting Officer & VP who has filed 9 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing shows the insider sold $1.8K of QNCX on Mar 6, 2023. Across all open-market trades the lifetime net is −$1.8K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $25.6K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$25.6K
2
9
-$1.8K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| QNCX | Chief Accounting Officer & VP | 27,440 | $0.93 | $25.6K | -$1.8K | 4 | 2023-03-06 |
| Quince Therapeutics, Inc. (CRTX) Delisted | Chief Accounting Officer & VP | 32,471 | $1.95 | $63.3K | $0 | 5 | 2022-07-01 |
Recent Filings
9 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-03-06 | QNCX | Sell (S) | −1,871 | -$1.8K | EDGAR |
| 2023-02-02 | QNCX | Grant (A) | — | $0 | EDGAR |
| 2022-12-07 | QNCX | Tax (F) | −1,640 | -$1.2K | EDGAR |
| 2022-09-08 | QNCX | Tax (F) | −1,520 | -$2.5K | EDGAR |
| 2022-07-01 | Quince Therapeutics, Inc. (CRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-08 | Quince Therapeutics, Inc. (CRTX) Delisted | Tax (F) | −1,529 | -$4.8K | EDGAR |
| 2022-03-04 | Quince Therapeutics, Inc. (CRTX) Delisted | Grant (A) | +34,000 | $0 | EDGAR |
| 2022-01-05 | Quince Therapeutics, Inc. (CRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-02-11 | Quince Therapeutics, Inc. (CRTX) Delisted | Grant (A) | — | $0 | EDGAR |